RxSight, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
RxSight (RXST) officer Ilya Goldshleger plans to sell 5,370 shares of company stock to cover withholding taxes on vested restricted stock units, according to a Rule 144 notice filed on September 2, 2026, with the sale scheduled for August 31, 2026.
RxSight (RXST) reported that Chief Business Development Officer Eric Weinberg converted 5,370 RSUs into shares and sold 2,041 shares at $6.96 to cover taxes. Weinberg retains indirect holdings and significant RSUs set to vest by 2029. No discretionary sale or 10b5-1 plan was involved.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported a 6.0% stake in RxSight, Inc. (RXST), owning 2,487,468 shares as of August 18, 2026. The shares are held by Point72 Associates, LLC, with shared voting and dispositive power.
Over the past 7 days, alphai's AI scored 4 news stories mentioning RXST (RxSight, Inc.). Coverage has been balanced: 0 bullish, 4 neutral, and 0 bearish.
Recent RXST coverage spans financial news, technology and earnings.
In the last 30 days, RXST insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($118K). The most active reporter was Goldshleger Ilya, Chief Operating Officer, with 1 filing.
A small insider sale of 5,370 shares is disclosed, indicating modest additional supply but limited price impact.
Minor insider sell of ~$14K; unlikely to move the stock.
The new stake may signal confidence and could influence future board decisions or potential activist interest.
The deal extends RxSight’s technology into a broader PCIOL offering, potentially expanding addressable market and royalty revenue streams.
Simply Wall St discusses Alcon’s Q2 2026 earnings, saying sales and revenue rose but net income fell, while 2026 net sales growth guidance was maintained. It also cites a RxSight collaboration and notes Alcon’s shares returned 17.97% over 90 days but -13.93% over one year. A “fair value” of CHF76.62 vs CHF59.48 is referenced.
alphai scores every news story that mentions RXST with an AI model for sentiment and relevance, and aggregates insider trades from RxSight, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RxSight (RXST) officer Ilya Goldshleger plans to sell 5,370 shares of company stock to cover withholding taxes on vested restricted stock units, according to a Rule 144 notice filed on September 2, 2026, with the sale scheduled for August 31, 2026.
1 min readRxSight (RXST) reported that Chief Business Development Officer Eric Weinberg converted 5,370 RSUs into shares and sold 2,041 shares at $6.96 to cover taxes. Weinberg retains indirect holdings and significant RSUs set to vest by 2029. No discretionary sale or 10b5-1 plan was involved.
1 min readPoint72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen reported a 6.0% stake in RxSight, Inc. (RXST), owning 2,487,468 shares as of August 18, 2026. The shares are held by Point72 Associates, LLC, with shared voting and dispositive power.
1 min readAlcon and RxSight announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses. RxSight’s Light Adjustable Lens is described as FDA-approved and adjustable after surgery via non-invasive light treatments. Alcon will lead global commercialization, RxSight will handle development and manufacturing and receive royalties on net sales.
3 min readSimply Wall St discusses Alcon’s Q2 2026 earnings, saying sales and revenue rose but net income fell, while 2026 net sales growth guidance was maintained. It also cites a RxSight collaboration and notes Alcon’s shares returned 17.97% over 90 days but -13.93% over one year. A “fair value” of CHF76.62 vs CHF59.48 is referenced.
6 min readRxSight (RXST) held its Q2 2026 earnings call. The company said it withdrew full-year 2026 guidance and will resume formal guidance in early 2027. Q2 total revenue was $33.7M, including $6.5M from an Alcon collaboration. Product sales were $27.2M, down 19% YoY, with a Q2 net loss of $12.1M.
6 min readAlcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST) announced a non-exclusive collaboration to co-develop post-operative adjustable pseudophakic intraocular lenses using RxSight’s light-adjustable technology. Alcon also opened a second training center in India with Aravind. Q1 2026: Alcon net sales $2.7B (+10% YoY), core EPS $0.85, FCF $279M. RxSight revenue $30.9M (-18.5% YoY), net loss $15.9M, gross margin 76.1%.
6 min readRxSight, Inc. (RXST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 RXSIGHT, INC. REPORTS SECOND QUARTER 2026 RESULTS AND PROVIDES UPDATE ON 2026 OUTLOOK Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financia
6 min readRxSight, Inc. said filings show Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander beneficially own 3,030,287 shares, or 7.3% of the common stock class, as of June 30, 2026. The entities report shared voting and dispositive power, with a Joint Filing Agreement dated Aug. 3, 2026.
2 min readRxSight says its Light Adjustable Lens (LAL) has been implanted in more than 325,000 cases and is now available in Australia after inclusion on the ARTG. The company describes a post-surgery “test drive” using UV light treatments to fine-tune refractive outcomes, with up to three adjustments and final “lock-in” therapy. RxSight reports over 2,000 surgeons using the LAL internationally.
6 min read
